IBA releases the RAZOR Nano Chamber

Dosimetry
/
20.09.2017

IBA releases the world’s smallest ionization chamber. 
The RAZOR Nano Chamber enables more precise stereotactic beam scanning.

Schwarzenbruck, September 20, 2017 – IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy solutions and radiation therapy integrated quality assurance (QA) for the treatment of cancer, announced the release of the RAZOR Nano Chamber, the smallest available ionization chamber in the market worldwide. 


With its beam quality independent characteristic and the spherical shape of its active volume, the RAZOR Nano Chamber is the latest highlight for small field dosimetry at IBA.
The waterproof, ventilated small ionization chamber with enhanced long-term stability, an extremely small diameter of 2 mm and a cavity volume of only 0.003 ccm allows measurements of small fields (< 2x2 cm) with a high spatial resolution and low penumbra values.

Reggiori et al. recently published their findings of the RAZOR Nano Chamber study1: “An interesting feature of the Nanochamber is its beam quality independence and, as a future development, the possibility to use it for small field absolute dosimetry”.  

“We are very excited to officially announce the release of the RAZOR Nano Chamber to further strengthen our Small Field Dosimetry portfolio” says Christian Neumeier, Marketing Specialist for Relative and Absolute Dosimetry at IBA Dosimetry.
“I’m proud to say that this is not only the smallest ionization chamber in the market worldwide, it is also the perfect detector for use in combination with our perturbation-free reference signal chamber, the Stealth Chamber, for achieving highest precision in very Small Field Dosimetry”.

The RAZOR Nano Chamber has officially received the CE mark.


For more information please visit: www.iba-dosimetry.com
_________________________

 

1 Reggiori G. et al. Small field characterization of a Nanochamber prototype under flattening filter free photon beams. Phys. Med. (2017). http://dx.doi.org/10.1016/j.ejmp.2017.08.007

                                                                      
                                                                         ***ends***



About IBA Dosimetry

IBA Dosimetry GmbH innovates radiation therapy, proton therapy and diagnostic imaging through integrated Quality Assurance solutions that are efficient, intuitive and that provide peace of mind for healthcare professionals and patients around the world. The myQA® Global QA Platform is the backbone for Integrated Quality Assurance solutions. IBA Dosimetry has more than 220 international employees in four offices in Germany, France, China and USA.

Find more information at: www.iba-dosimetry.com


About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com


Contact:

Christian Neumeier
Marketing Specialist
IBA Dosimetry
Christian.Neumeier@iba-dosimetry.com
www.iba-dosimetry.com

Share
Download